Partner A was OptimizeRx’s largest revenue line in fiscal 2024, bringing in $26.82M of $92.11M (29%).
| Customer | FY 2014 | FY 2017 | FY 2018 | FY 2019 | FY 2024 |
|---|---|---|---|---|---|
| Partner A | $26.82M | ||||
| Partner B | $25.98M | ||||
| Customer A | $15.56M | ||||
| Customer B | $12.76M | ||||
| Partner C | $11.00M | ||||
| Partner B[Member] | — | ||||
| Customer D Lilly | — | ||||
| All Other Customers | — | ||||
| Customer E Pfizer | — | ||||
| Customer E | — | ||||
| Customer C | — | ||||
| Customer Three | — | ||||
| Partner D | — | ||||
| Customer D | — | ||||
| Customer Four | — | ||||
| Customer | — | ||||
| Customer One | — | ||||
| Customer Two | — | ||||
| Total | $92.11M |
OptimizeRx brought in $92.11M from its five revenue lines in fiscal 2024, the year ended December 31, 2024. Partner A was the largest at $26.82M (29.1%), ahead of Partner B at $25.98M (28.2%) and Customer A at $15.56M (16.9%). The other two revenue lines brought in $23.76M combined.
Revenue Recognized Over Time was OptimizeRx’s largest revenue line in fiscal 2024, bringing in $85.47M of $92.13M (93%).
| Timing of Transfer of Good or Service | FY 2023 | FY 2024 |
|---|---|---|
| Revenue Recognized Over Time | $63.53M | $85.47M |
| Revenue Recognized At A Point In Time | $8.00M | $6.66M |
| Total | $71.52M | $92.13M |
OptimizeRx brought in $92.13M from its two revenue lines in fiscal 2024, the year ended December 31, 2024. That was up 28.8% from $71.52M in fiscal 2023. Revenue Recognized Over Time was the largest at $85.47M (92.8%), ahead of Revenue Recognized At A Point In Time at $6.66M (7.2%).
Compared with fiscal 2023, Revenue Recognized Over Time grew 34.5% to $85.47M, while Revenue Recognized At A Point In Time fell 16.7% to $6.66M.
Scenario Previously Reported was OptimizeRx’s largest revenue line in fiscal 2013, bringing in $4.96M of $4.68M (106%).
| Report Date | FY 2013 |
|---|---|
| Scenario Previously Reported | $4.96M |
| Restatement Adjustment | -$277.28K |
| Total | $4.68M |
OptimizeRx brought in $4.68M from its two revenue lines in fiscal 2013, the year ended December 31, 2013. Scenario Previously Reported was the largest at $4.96M (105.9%).
The total is net of Restatement Adjustment, which took $277.28K off revenue in fiscal 2013.
OptimizeRx (OPRX) reports its revenue by customer, by timing of transfer of good or service and by report date. In fiscal 2024, Partner A was its largest revenue line, bringing in $26.82M (29.1% of the total), followed by Partner B at $25.98M (28.2%).
Partner A was OptimizeRx's largest revenue line in fiscal 2024, bringing in $26.82M, or 29.1% of the $92.11M total across its five revenue lines.
Revenue Recognized Over Time grew faster than Revenue Recognized At A Point In Time in fiscal 2024, up 34.5% from $63.53M to $85.47M. Revenue Recognized At A Point In Time fell 16.7% to $6.66M.
Every figure comes from OptimizeRx's annual financial filings, as reported. Each line keeps the name OptimizeRx gives it, and years follow its fiscal calendar.
OptimizeRx's revenue by customer goes back to fiscal 2014, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.